GlassScriptPhysician profile
Paul B Kirsch
NPI 1598759128
$7,495.51
in general payments reported to CMS, 2019-2025
29 companies · $70.24 in 2025
The $70.24 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,056 · 2020: $1,707 · 2021: $1,747 · 2022: $1,618 · 2024: $297 · 2025: $70.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,399.21 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,076.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $595.33 | 2019-2022 | |
| Pfizer INC. | $534.20 | 2019-2021 | |
| Amgen INC. | $448.10 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.41 | 2019-2022 | |
| Novo Nordisk INC | $385.97 | 2019-2024 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $357.18 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $298.78 | 2022-2024 | |
| Abbvie INC. | $243.72 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $243.10 | 2019-2020 | |
| Lilly USA, LLC | $224.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $221.25 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $180.28 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $163.69 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $160.85 | 2022 | |
| Amarin Pharma, INC. | $104.84 | 2020-2021 | |
| Exact Sciences Corporation | $93.72 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $70.24 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Allergan, INC. | $59.53 | 2019-2020 | |
| Grifols USA, LLC | $55.97 | 2021 | |
| Esperion Therapeutics, INC. | $40.98 | 2020-2021 | |
| Shire North American Group INC | $20.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.31 | 2020 | |
| Tactile Systems Technology INC | $19.91 | 2020 | |
| Boston Scientific Corporation | $14.85 | 2019 | |
| Astellas Pharma US INC | $12.08 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.